IA
GNOM icon

Insight Advisors’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Insight Advisors’s Portfolio GNOM Stock Details GNOM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,913
Closed -$579K – 293
2025
Q3 		$579K Sell
14,913
-6
-0% -$217 0.09% 145
2025
Q2 		$503K Buy
14,919
+4,830
+48% +$153K 0.08% 156
2025
Q1 		$321K Buy
10,089
+2,791
+38% +$106K 0.06% 201
2024
Q4 		$282K Buy
7,298
+1,235
+20% +$51.9K 0.05% 234
2024
Q3 		$273K Buy
6,063
+769
+15% +$34.4K 0.05% 245
2024
Q2 		$221K Buy
5,294
+1,965
+59% +$82.1K 0.04% 269
2024
Q1 		$152K Buy
+3,329
New +$152K 0.03% 286
2023
Q2 		– Sell
-5,357
Closed -$264K – 300
2023
Q1 		$264K Sell
5,357
-1,013
-16% -$52.1K 0.06% 244
2022
Q4 		$319K Sell
6,370
-1,392
-18% -$71.8K 0.11% 230
2022
Q3 		$390K Sell
7,762
-157
-2% -$8.86K 0.15% 175
2022
Q2 		$486K Buy
7,919
+414
+6% +$21K 0.16% 156
2022
Q1 		$451K Buy
7,505
+1,359
+22% +$85.7K 0.14% 190
2021
Q4 		$488K Buy
+6,146
New +$516K 0.14% 173

Other funds holding GNOM

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
OAM
Oppenheimer Asset Management New York $8.76B AUM 23.12% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
IWM
IHT Wealth Management Chicago, Illinois $4.3B AUM 21.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
USCWA
U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Insight Advisors's GNOM Position: Q4 2025 in Review

Insight Advisors sold out of Global X Genomics & Biotechnology ETF (GNOM) in Q4 2025, closing a stake of 14,913 shares — an estimated $579K sold.

Insight Advisors first reported a position in GNOM in Q4 2021 and held it in 13 quarters. The position peaked at $579K in Q3 2025. 40 funds tracked by Wall St. Rank hold GNOM as of Q4 2025.

  • Insight Advisors reported no remaining Global X Genomics & Biotechnology ETF position as of Q4 2025 after selling out during the quarter.
  • Insight Advisors sold 14,913 Global X Genomics & Biotechnology ETF shares in Q4 2025, an estimated $579K.
  • Insight Advisors first reported a position in Global X Genomics & Biotechnology ETF in Q4 2021 and held it in 13 quarters.
  • Insight Advisors's Global X Genomics & Biotechnology ETF position peaked at $579K in Q3 2025.
  • 40 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q4 2025.

Based on Insight Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.